• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Friday 5 from Rheumatology Network - April 30

Article

The Friday 5 from Rheumatology Network is a list composed by the Rheumatology Network editorial staff aimed at highlighting relevant coverage of the latest news in rheumatology.

This week, the Friday 5 from Rheumatology Network highlights the latest psoriatic arthritis news and a new mental health education program designed to reduce anxiety and depression in patients with rheumatic disease during the COVID-19 pandemic.

The SPIN-CHAT Program was developed by investigators in order to help participants deal with isolation and learn better mental health coping mechanisms.

“In this large, multiethnic, single-center, cohort study of children born to anti-Ro antibody positive mothers, the child’s ethnicity was not associated with NLE risk, nor specific NLE manifestations,” stated investigators.

Investigators observed that patients treated with secukinumab were more likely to achieve Psoriasis Area Severity Index (PASI) 75/90/100 responses and Investigator’s Global Assessment (IGA) improvement at 52 weeks than those administered usetkinumab, regardless of their psoriatic arthritis (PsA) status.

This week, Rheumatology Network sat down with Philip J. Mease, MD, to discuss his study, “Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.”

“The sustained benefits for patients with active psoriatic arthritis across multiple domains indicate that guselkumab may offer a novel mechanism by which to provide extended improvements in the diverse manifestations of psoriatic arthritis,” Laura Coates, PhD, and team concluded.

Related Videos
Victor J. Dzau, MD, gives expert advice
Victor J. Dzau, MD, gives expert advice
Monica Verduzco-Gutierrez, MD, FAAPMR, gives expert advice
Monica Verduzco-Gutierrez, MD, FAAPMR, gives expert advice
Monica Verduzco-Gutierrez, MD, FAAPMR, gives expert advice
Monica Verduzco-Gutierrez, MD, FAAPMR, gives expert advice
Monica Verduzco-Gutierrez, MD, FAAPMR, gives expert advice
Monica Verduzco-Gutierrrez, MD, FAAPMR, gives expert advice